文献速递脑血管病

癌症病史是否影响他汀类药物对卒中后结局的疗效?

Does a History of Cancer Influence the Effectiveness of Statins on Outcomes After Stroke?
PubMed 文献 · Stroke · 2022-09-06

基于2012至2016年45家医院缺血性卒中90天存活者的登记与行政数据联动分析,纳入9948例参与者,中位年龄72岁,女性占42%,随访期间死亡1463例。倾向评分校正后,出院90天内配发他汀与癌症病史在死亡率上无统计学交互作用(P=0.156),但存在显著的生物学交互作用,提示卒中后他汀治疗可能为有癌症病史者带来额外生存获益。

要点

  • 在9948例缺血性卒中90天存活者中,出院90天内配发他汀与癌症病史对死亡率无统计学交互作用(P=0.156)。
  • 配发他汀与癌症病史对死亡率存在显著正生物学交互作用:相对超额风险归因于交互作用为2.80(95%CI 1.56-5.05)。
  • 归因于交互作用的可归因比例为0.45(95%CI 0.23-0.66),协同指数为2.14(95%CI 1.32-3.49)。

核心结论

  • 缺血性卒中后接受他汀类药物治疗可能为同时有癌症病史者带来额外生存获益。

研究设计与样本

  • 利用登记与行政数据联动,分析2012至2016年45家医院缺血性卒中90天存活者,从出院后第91天随访至死亡或2018年6月30日。
  • 从药品记录确定出院后90天内他汀配发情况,从医院数据确定癌症病史,采用倾向评分校正的Cox比例风险回归模型分析他汀配发与生存的关联。
  • 通过统计交互作用与生物学交互作用(相对超额风险归因于交互作用>0、归因于交互作用的可归因比例>0、协同指数>1)评估癌症病史对该关联的影响。

主要发现

  • 共纳入9948例符合条件的参与者,中位年龄72岁,女性占42%,随访期间发生1463例死亡。
  • 校正分析中,配发他汀与癌症病史对死亡率无统计学交互作用(P=0.156)。
  • 配发他汀与癌症病史对死亡率存在显著正生物学交互作用:相对超额风险归因于交互作用为2.80(95%CI 1.56-5.05)。
  • 归因于交互作用的可归因比例为0.45(95%CI 0.23-0.66),协同指数为2.14(95%CI 1.32-3.49)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence is growing on anticancer effects of statins. We investigated whether the effectiveness of treatment with statins after ischemic stroke on mortality is influenced by a history of cancer. METHODS: Analyses of 90-day survivors of ischemic stroke (2012-2016; 45 hospitals) using linked registry and administrative data. Dispense of statins within 90 days postdischarge was determined from pharmaceutical records. Participants were followed from 91 days postdischarge until death or June 30, 2018. History of cancer was determined from hospital data. Propensity score-adjusted Cox proportional hazards regression model was used to determine the association between being dispensed statins and survival. The influence of history of cancer on this association was assessed based on the concepts of (1) statistical interaction and (2) biological interaction using 3 indices: relative excess risk due to interaction>0, attributable proportion due to interaction >0, or synergy index >1. RESULTS: Among 9948 eligible participants (median age=72 years, 42% female), there were 1463 deaths. In adjusted analyses, there was no statistical interaction between being dispensed statins and history of cancer on mortality (P=0.156). However, being dispensed statins had a significant positive biological interaction with having a history of cancer on mortality: relative excess risk due to interaction, 2.80 (95% CI, 1.56-5.05), attributable proportion due to interaction, 0.45 (95% CI, 0.23-0.66), and synergy index, 2.14 (95% CI, 1.32-3.49). CONCLUSIONS: Treatment with statins after ischemic stroke may confer additional survival benefits for people who also have had cancer.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Olaiya MT, Andrew NE, Dalli LL, et al. Does a History of Cancer Influence the Effectiveness of Statins on Outcomes After Stroke? Stroke. 2022. PMID: 36065808. doi:10.1161/STROKEAHA.122.038829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。